文献速递神经肿瘤

超级T2-FLAIR错配征:非强化IDH突变型星形细胞瘤的预后影像生物标志物

Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.
PubMed 文献 · J Neurooncol · 2024-07-12

本研究回顾性分析本院31例和TCGA/TCIA 30例非强化IDH突变型星形细胞瘤,定义「超级T2-FLAIR错配征」为非囊性病灶出现与脑脊液相当的显著低信号。该征象在本院和TCGA-LGG数据集分别检出8例(26%)和13例(43%),与更长的无进展生存期和总生存期相关。

要点

  • 超级T2-FLAIR错配征定义为非囊性病灶在FLAIR上呈与脑脊液相当的显著低信号。
  • 本院检出该征象者无进展生存期122.7个月 vs 35.9个月(p=0.0491)。
  • TCGA-LGG数据集中该征象与更长总生存期相关(未达到 vs 44.0个月,p=0.0177)。

核心结论

  • 超级T2-FLAIR错配征是非强化IDH突变型星形细胞瘤有前景的预后影像生物标志物。

研究设计与样本

  • 回顾性分析本院31例非强化IDH突变型星形细胞瘤及TCGA/TCIA 30例。
  • 定义超级T2-FLAIR错配征为非囊性病灶出现与脑脊液相当的显著低信号,囊性病灶(圆形或椭圆形)排除在标准之外。
  • 采用术前MRI评估T2-FLAIR错配征及超级T2-FLAIR错配征,以log-rank检验分析无进展生存期和总生存期。

主要发现

  • T2-FLAIR错配征在本院17例(55%)、TCGA-LGG数据集9例(30%)中检出,与无进展生存期或总生存期均无相关性。
  • 超级T2-FLAIR错配征在本院8例(26%)、TCGA-LGG数据集13例(43%)中检出。
  • 本院超级T2-FLAIR错配征阳性者无进展生存期显著延长(122.7 vs 35.9个月,p=0.0491),总生存期显著延长(未达到 vs 116.7个月,p=0.0232)。
  • TCGA-LGG数据集中超级T2-FLAIR错配征阳性者总生存期显著更长(未达到 vs 44.0个月,p=0.0177)。

关键数值与推荐

  • 超级T2-FLAIR错配征:非囊性病灶在FLAIR上呈与脑脊液相当的显著低信号,而非传统T2-FLAIR错配征的淡薄低信号。
  • 囊性病灶定义为圆形或椭圆形,排除在超级T2-FLAIR错配征标准之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The T2-FLAIR mismatch sign is a highly specific diagnostic imaging biomarker for astrocytoma, IDH-mutant. However, a definitive prognostic imaging biomarker has yet to be identified. This study investigated imaging prognostic markers, specifically analyzing T2-weighted and FLAIR images of this tumor. METHODS: We retrospectively analyzed 31 cases of non-enhancing astrocytoma, IDH-mutant treated at our institution, and 30 cases from The Cancer Genome Atlas (TCGA)/The Cancer Imaging Archive (TCIA). We defined "super T2-FLAIR mismatch sign" as having a significantly strong low signal comparable to cerebrospinal fluid at non-cystic lesions rather than just a pale FLAIR low-signal tumor lesion as in conventional T2-FLAIR mismatch sign. Cysts were defined as having a round or oval shape and were excluded from the criteria for the super T2-FLAIR mismatch sign. We evaluated the presence or absence of the T2-FLAIR mismatch sign and super T2-FLAIR mismatch sign using preoperative MRI and analyzed the progression-free survival (PFS) and overall survival (OS) by log-rank test. RESULTS: The T2-FLAIR mismatch sign was present in 17 cases (55%) in our institution and 9 cases (30%) within the TCGA-LGG dataset without any correlation with PFS or OS. However, the super T2-FLAIR mismatch sign was detected in 8 cases (26%) at our institution and 13 cases (43%) in the TCGA-LGG dataset. At our institution, patients displaying the super T2-FLAIR mismatch sign showed significantly extended PFS (122.7 vs. 35.9 months, p = 0.0491) and OS (not reached vs. 116.7 months, p = 0.0232). Similarly, in the TCGA-LGG dataset, those with the super T2-FLAIR mismatch sign exhibited notably longer OS (not reached vs. 44.0 months, p = 0.0177). CONCLUSION: The super T2-FLAIR mismatch is a promising prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ozono I, Onishi S, Yonezawa U, et al. Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant. J Neurooncol. 2024. PMID: 38995493. doi:10.1007/s11060-024-04758-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。